Mebendazole Tablets
This product is not discontinued or withdrawn for safety or efficacy reasons. The Mebendazole 100 mg Tablets currently available in pharmacies can continue to be.
Learn about the prescription medication Vermox Mebendazole, drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling.
Mebendazole (MBZ) is a medication used to treat a number of parasitic worm infestations. This includes ascariasis, pinworm disease, hookworm infections, guinea worm infections, hydatid disease, and giardia, among others. It is taken by mouth. Mebendazole is usually well tolerated. Common side effects include headache, vomiting, and ringing in the ears. If used at large doses it may cause bone marrow suppression. It is unclear if it is safe in pregnancy. Mebendazole is a broad-spectrum antihelminthic agent of the benzimidazole type. Mebendazole came into use in 1971. It is included in the WHO Model List of Essential Medicines, the most important medications needed in a basic health system. Mebendazole is available as a generic medication. The wholesale cost is between 0.004 and 0.04 USD per dose. In the United States a single dose is about 18 USD. Mebendazole is a highly effective, broad-spectrum antihelmintic indicated for the treatment of nematode infestations, including roundworm, hookworm, whipworm, threadworm, pinworm, and the intestinal form of trichinosis prior to its spread into the tissues beyond the digestive tract. Other drugs are used to treat worm infections outside the digestive tract, as mebendazole is poorly absorbed into the bloodstream. Mebendazole is used alone in those with mild to moderate infestations. It kills parasites relatively slowly, and in those with very heavy infestations, it can cause some parasites to migrate out of the digestive system, leading to appendicitis, bile duct problems, or intestinal perforation. To avoid this, heavily infested patients may be treated with piperazine, either before or instead of mebendazole. Piperazine paralyses the parasites, causing them to pass in the feces. It is also used rarely in the treatment of hydatid disease. Evidence for effectiveness for this disease, however, is poor. Mebendazole and other benzimidazole antithelmetics are active against both larval and adult stages of nematodes, and in the cases of roundworm and whipworm, kill the eggs, as well. Paralysis and death of the parasites occurs slowly, and elimination in the feces may require several days. Mebendazole is pregnancy category C, which means it has been shown to cause ill effects in pregnancy in animal models, and no adequate studies of its effects in human pregnancy have been conducted. Whether it can be passed by breastfeeding is unknown. Mebendazole sometimes causes diarrhea, abdominal pain, and elevated liver enzymes. In rare cases, it has been associated with a dangerously low white blood cell count, low platelet count, and hair loss, with a risk of agranulocytosis in rare cases Carbamazepine and phenytoin lower serum levels of mebendazole. Cimetidine does not appreciably raise serum mebendazole (in contrast to the similar drug albendazole), consistent with its poor systemic absorption. Stevens–Johnson syndrome and the more severe toxic epidermal necrolysis can occur when mebendazole is combined with high doses of metronidazole. Mebendazole is thought to work by selectively inhibiting the synthesis of microtubules in parasitic worms, and by destroying extant cytoplasmic microtubes in their intestinal cells, thereby blocking the uptake of glucose and other nutrients, resulting in the gradual immobilization and eventual death of the helminths. Mebendazole is available as a generic medication. The wholesale cost is between 0.004 and 0.04 USD per dose. In the United States a single dose is about 18 USD. Mebendazole is distributed in international markets by Johnson and Johnson and a number of generic manufacturers. Several studies show mebendazole exhibits potent antitumor properties. MBZ significantly inhibited cancer cell growth, migration, and metastatic formation of adrenocortical carcinoma, both in vitro and in vivo. Treatment of lung cancer cell lines with MBZ caused mitotic arrest, followed by apoptotic cell death with the feature of caspase activation and cytochrome c release. MBZ induced a dose- and time-dependent apoptotic response in human lung cancer cell lines, and apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells.
Drugs to be Discontinued: Mebendazole Tablets. Wednesday, Mebendazole Tablets10/26/2011Teva Pharmaceuticals1-800-545-8800 Dear Valued Customer Letter.
Select Page Home About Us What We Do Strategic Plan Our Leadership New Logo and Tagline Our History Awards Nominations and Elections ASHP Careers For the Press Member Center Join/Renew Manage My Account Membership Benefits Sections and Forums On Demand Webinars InterSections FAQs Education Continuing Education eLearning Home Study Activities Webinars Specialty Certifications Traineeships Practice & Policy Policies & Guidelines Resource Centers House of Delegates PAI Events Meetings & Conferences Calendar of Events Get Involved in a Meeting For Presenters Advocacy Advocacy Agenda Federal Issues State Advocacy Policy Analysis and Alerts Grassroots Network ASHP PAC News Pharmacy News News Capsules Press Releases ASHP in the News RSS Feeds Photo Gallery Residencies Residency Directory Program Information Applicant Information Residency Resources Technicians Technician Training Directory Technician Accreditation Store Publications eBooks For Authors Help & Support Mebendazole tablets, Teva 100 mg tablets, 12 count (NDC 00093-9107-29) Reason for the Shortage Teva discontinued mebendazole tablets in October, 2011. Teva did not provide a reason for discontinuing mebendazole tablets. The customer letter is available online. Teva was the sole manufacturer of mebendazole tablets. Updated October 27, 2011, University of Utah, Drug Information Service. Copyright 2011, Drug Information Service, University of Utah, Salt Lake City, UT. Disclaimer This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug. « Back to Drug Shortage Product Bulletins About ASHP ASHP is the national professional organization whose more than 40,000 members include pharmacists, student pharmacists, and pharmacy technicians who serve as patient care providers on healthcare teams in acute and ambulatory settings.
Reason for the Shortage. Teva discontinued mebendazole tablets in October, 2011. Teva did not provide a reason for discontinuing mebendazole tablets.
Mebendazole
Mebendazole MBZ is a medication used to treat a number of parasitic worm infestations. 2 This includes ascariasis, pinworm disease, hookworm infections.
What is Mebendazole. 6- It s discontinued in the United States and no reason is given for its 3- I have no idea why this topic is not covered here on.